GleamWall
中文EN

AVBP ArriVent BioPharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1868279 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-11.7%
TTM EPS YoY13.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-48.4%
ROA-45.5%
ROIC (approx.)-60.6%
Asset turnover—

Leverage & solvency

Liabilities / assets5.7%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$153.35M$79.00M
SG&A expense$24.18M$15.30M
Operating income-$177.53M-$94.31M
Net income-$166.31M-$80.49M
EBITDA-$180.56M—
EPS (basic)-4.32-2.56
EPS (diluted)-4.32-2.56
Weighted avg. shares (diluted)38.46M31.47M
Balance sheet
Cash & equivalents$45.54M$74.29M
Short-term investments$267.28M$144.57M
Current assets$332.90M$226.98M
Total assets$333.17M$274.94M
Current liabilities$25.95M$17.27M
Total liabilities$25.95M$17.29M
Shareholders' equity$307.22M$257.65M
Shares outstanding42.45M33.71M
Cash flow statement
Operating cash flow-$160.59M-$70.21M
Investing cash flow-$71.23M-$192.47M
Financing cash flow$203.06M$186.58M
Depreciation & amortization-$3.03M—
Stock-based compensation$12.52M$3.21M

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.